Show simple item record

dc.contributor.authorJackisch, C.
dc.contributor.authorManevy, F.
dc.contributor.authorFrank, S.
dc.contributor.authorRoberts, N.
dc.contributor.authorShafrin, J.
dc.date.accessioned2022-01-31T15:49:09Z
dc.date.available2022-01-31T15:49:09Z
dc.date.issued2022en
dc.identifier.citationJackisch C, Manevy F, Frank S, Roberts N, Shafrin J. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example COMMENT. Adv Ther.12.en
dc.identifier.pmid34988876en
dc.identifier.doi10.1007/s12325-021-01996-0en
dc.identifier.urihttp://hdl.handle.net/10541/625030
dc.description.abstractHealth technology assessments and value frameworks are becoming increasingly important for clinical decision-making. Most of these frameworks, however, focus on value to payers rather than patients and healthcare providers and may ignore other sources of economic value such as patient and physician time cost, impact on productivity, and direct health system costs. This article focusses on fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive breast cancer. We review relevant clinical evidence, examine data on time and resource use of the subcutaneous administration of trastuzumab compared with intravenous treatment and how it can be extrapolated to PH FDC SC, and discuss the value PH FDC SC can bring to patients and healthcare providers. We will also provide our own experiences of PH FDC SC from the healthcare (oncologist, healthcare economist, pharmacist) and patient point of view. The data, combined with our personal experiences, suggest that switching from intravenous pertuzumab and trastuzumab to PH FDC SC could reduce non-drug costs for healthcare providers treating patients with HER2-positive breast cancer through time savings and other economic benefits. Furthermore, PH FDC SC could also save patient time given its shorter administration and post-injection observation time versus intravenous infusions, potentially resulting in reduced productivity loss. These benefits could be applied to other subcutaneous formulations, either currently available or in development.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s12325-021-01996-0en
dc.titleWhite Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example COMMENTen
dc.typeArticleen
dc.contributor.departmentAGO-B and Sana Klinikum Offenbach GmbH, Offenbach, Germanyen
dc.identifier.journalAdvances in Therapyen
dc.description.noteen]
refterms.dateFOA2022-04-19T12:25:30Z


Files in this item

Thumbnail
Name:
34988876.pdf
Size:
1.189Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record